{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:54:51Z","timestamp":1785876891458,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cellsig.2026.112637","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:31:41Z","timestamp":1780759901000},"page":"112637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK\/MAPK signaling"],"prefix":"10.1016","volume":"146","author":[{"given":"Haomin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cellsig.2026.112637_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70162","article-title":"Pancreatic cancer: pathogenesis and clinical studies","volume":"6","author":"Zhou","year":"2025","journal-title":"MedComm"},{"issue":"43","key":"10.1016\/j.cellsig.2026.112637_bb0010","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"19","key":"10.1016\/j.cellsig.2026.112637_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910843","article-title":"Molecular targets for the diagnosis and treatment of pancreatic cancer","volume":"25","author":"Pergolizzi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112637_bb0020","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ijms25031389","article-title":"Multiplexed imaging mass cytometry analysis in preclinical models of pancreatic cancer","volume":"25","author":"Erreni","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112637_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112637_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112637_bb0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellsig.2026.112637_bb0040","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3850839","article-title":"Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects","author":"Guo","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cellsig.2026.112637_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601756","article-title":"Chemokines: humble yet mighty players in the tumour microenvironment","volume":"16","author":"Xavier","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0050","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2538962","article-title":"Dual role of CXCL10 in cancer progression: implications for immunotherapy and targeted treatment","volume":"26","author":"Madkhali","year":"2025","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112637_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199802123380706","article-title":"Chemokines--chemotactic cytokines that mediate inflammation","volume":"338","author":"Luster","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.182.1.155","article-title":"Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo","volume":"182","author":"Angiolillo","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellsig.2026.112637_bb0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2021.03.002","article-title":"Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10\/CXCR3 axis in hepatocellular carcinoma (HCC)","volume":"506","author":"Yan","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/19768354.2024.2402024","article-title":"CXCL10 promotes melanoma angiogenesis and tumor growth","volume":"28","author":"Kim","year":"2024","journal-title":"Animal Cells and Systems"},{"issue":"3","key":"10.1016\/j.cellsig.2026.112637_bb0075","first-page":"402","article-title":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University","volume":"51","author":"Zhang","year":"2019","journal-title":"Health Sciences"},{"key":"10.1016\/j.cellsig.2026.112637_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100690","article-title":"The metastatic role of the CXCL10-CXCR3 axis and its therapeutic potential in osteosarcoma","volume":"52","author":"Gyau","year":"2025","journal-title":"Journal of bone oncology"},{"key":"10.1016\/j.cellsig.2026.112637_bb0085","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.biopha.2016.04.069","article-title":"CXCL10\/CXCR3 axis promotes the invasion of gastric cancer via PI3K\/AKT pathway-dependent MMPs production","volume":"82","author":"Zhou","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112637_bb0090","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.7150\/ijbs.61350","article-title":"TNF-\u03b1 augments CXCL10\/CXCR3 axis activity to induce epithelial-mesenchymal transition in colon cancer cell","volume":"17","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112637_bb0095","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/0008-5472.CAN-06-3087","article-title":"CXCL10 promotes invasion-related properties in human colorectal carcinoma cells","volume":"67","author":"Zipin-Roitman","year":"2007","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0100","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00047-2016","article-title":"Pro-tumoural CXCL10\/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma","volume":"3","author":"Duruisseaux","year":"2017","journal-title":"ERJ Open Research"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0105","doi-asserted-by":"crossref","DOI":"10.1515\/med-2024-1117","article-title":"Unveiling the role of CXCL10 in pancreatic cancer progression: A novel prognostic indicator","volume":"20","author":"Wu","year":"2025","journal-title":"Open Medicine"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112637_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107764","article-title":"Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers","volume":"31","author":"Ozkan-Dagliyan","year":"2020","journal-title":"Cell Rep."},{"issue":"22","key":"10.1016\/j.cellsig.2026.112637_bb0115","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-20-1359","article-title":"CXCR3 and cognate ligands are associated with immune cell alteration and aggressiveness of pancreatic ductal adenocarcinoma","volume":"26","author":"Cannon","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"4_suppl","key":"10.1016\/j.cellsig.2026.112637_bb0120","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.2020.38.4_suppl.762","article-title":"Analysis of associations of CXCR3 ligands with immune microenvironment and aggressiveness in murine and human pancreatic ductal adenocarcinoma","volume":"38","author":"Cannon","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.cellsig.2026.112637_bb0125","article-title":"The Crosstalk with CXCL10-Rich tumor-associated mast cells fuels pancreatic cancer progression and immune escape","volume":"12","author":"Yin","year":"2025","journal-title":"Advanced Science (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"48","key":"10.1016\/j.cellsig.2026.112637_bb0130","doi-asserted-by":"crossref","first-page":"45098","DOI":"10.1074\/jbc.M106912200","article-title":"Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells","volume":"276","author":"Robledo","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112637_bb0135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.gendis.2023.04.007","article-title":"Pan-cancer immunogenic death analysis identifies key roles of CXCR3 and CCL18 in hepatocellular carcinoma","volume":"11","author":"Guo","year":"2023","journal-title":"Genes & diseases"},{"issue":"7","key":"10.1016\/j.cellsig.2026.112637_bb0140","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.trecan.2021.01.008","article-title":"Drivers of gene expression dysregulation in pancreatic cancer","volume":"7","author":"Venkat","year":"2021","journal-title":"Trends in Cancer"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12920-022-01246-4","article-title":"Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer","volume":"15","author":"Jing","year":"2022","journal-title":"BMC Med. Genomics"},{"issue":"2","key":"10.1016\/j.cellsig.2026.112637_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1615\/CritRevImmunol.2014010062","article-title":"Regulation of chemokine expression in the tumor microenvironment","volume":"34","author":"Gorbachev","year":"2014","journal-title":"Crit. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112637_bb0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-024-03761-y","article-title":"Tumor-intrinsic IFN\u03b1 and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment","volume":"73","author":"Cheng","year":"2024","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/j.cellsig.2026.112637_bb0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2015.00012","article-title":"Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges","volume":"6","author":"Vela","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellsig.2026.112637_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156335","article-title":"Chemokines and receptors in the development and progression of malignant tumors","volume":"170","author":"Zhao","year":"2023","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.cellsig.2026.112637_bb0170","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/ph14080740","article-title":"Epithelial to mesenchymal transition in patients with pancreatic ductal adenocarcinoma: state-of-the-art and therapeutic opportunities","volume":"14","author":"Dardare","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-020-00341-1","article-title":"Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cellsig.2026.112637_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0185","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1186\/s12885-021-08807-3","article-title":"Intraoperative radiation therapy induces immune response activity after pancreatic surgery","volume":"21","author":"Lee","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.cellsig.2026.112637_bb0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cellsig.2026.112637_bb0195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.12688\/f1000research.2-105.v1","article-title":"Advances in systemic therapy for advanced pancreatobiliary malignancies","volume":"2","author":"Halfdanarson","year":"2013","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0200","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12885-018-4384-8","article-title":"CXCL9\/10\/11, a regulator of PD-L1 expression in gastric cancer","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.cellsig.2026.112637_bb0205","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/0008-5472.CAN-23-3628","article-title":"VPAC2 receptor Signaling promotes growth and immunosuppression in pancreatic cancer","volume":"84","author":"Passang","year":"2024","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112637_bb0210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/biom3030435","article-title":"Altered sphingolipid metabolism in patients with metastatic pancreatic cancer","volume":"3","author":"Jiang","year":"2013","journal-title":"Biomolecules"},{"issue":"14","key":"10.1016\/j.cellsig.2026.112637_bb0215","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1074\/jbc.M312814200","article-title":"Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity","volume":"279","author":"Hensbergen","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0220","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12964-023-01453-1","article-title":"Natural carboxyterminal truncation of human CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic activity","volume":"22","author":"Dillemans","year":"2024","journal-title":"Cell Communication and Signaling\u202f: CCS"},{"issue":"8","key":"10.1016\/j.cellsig.2026.112637_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221169","article-title":"Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: enhancing diagnostic accuracy","volume":"14","author":"Kruger","year":"2019","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.cellsig.2026.112637_bb0230","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.cellsig.2026.112637_bb0235","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/mc.23509","article-title":"Systemic deuteration of SCID mice using the water-isotopologue deuterium oxide (D2 O) inhibits tumor growth in an orthotopic bioluminescent model of human pancreatic ductal adenocarcinoma","volume":"62","author":"Jandova","year":"2023","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.cellsig.2026.112637_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.760705","article-title":"Context matters-why we need to change from a one size fits all approach to made-to-measure therapies for individual patients with pancreatic cancer","volume":"9","author":"Sankarasubramanian","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.cellsig.2026.112637_bb0245","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/ueg2.70124","article-title":"Toward Precision chemotherapy for pancreatic Cancer guided by transcriptomic signatures","volume":"13","author":"Chanez","year":"2025","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112637_bb0250","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-13333-z","article-title":"Study protocol: multi-Centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2","volume":"25","author":"Kocher","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826002901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826002901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:40:03Z","timestamp":1785876003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826002901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S0898656826002901"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112637","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK\/MAPK signaling","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112637"}}